Loading clinical trials...
Loading clinical trials...
Multicenter Real-world Clinical Study of Inetetamab-based Therapy in HER2-positive Metastatic Breast Cancer
Conditions
Interventions
inetetamab
Locations
1
China
Liaoning Cancer Hospital &Institue
Shenyang, China
Start Date
July 1, 2022
Primary Completion Date
December 31, 2023
Completion Date
January 31, 2024
Last Updated
March 12, 2024
NCT06625775
NCT05800275
NCT06551116
NCT03417544
NCT05230810
NCT05042791
Lead Sponsor
Liaoning Cancer Hospital & Institute
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions